PHILADELPHIA, March 27, 2019 – Imvax, Inc., a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies, announced today that results from the Phase 1b clinical trial of lead product candidate IGV-001 for the treatment of newly diagnosed glioblastoma multiforme will be presented during an oral session in a Clinical Trials Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta.
Details of the presentation are as follows:
Title: Results of a Phase Ib trial of an autologous cell vaccine for newly diagnosed glioblastoma
Abstract Number: 7924
Session: Advances in Novel Immunotherapeutics
Date / Time: Sunday, March 31, 4:05 p.m. EDT
Location: Georgia World Congress Center, Room A411
Presenter: David Andrews, M.D.; Co-founder, Chief Medical Officer and interim Chief Executive Officer, Imvax, Inc., Philadelphia; Vice Chair, Clinical Services, Department of Neurological Surgery, Thomas Jefferson University, Philadelphia
Additional information on the meeting can be found on the AACR website: https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=174&DetailItemID=928.
IGV-001 is a first-in-class autologous vaccine in development for the treatment of newly diagnosed glioblastoma multiforme (GBM), a lethal and common type of brain tumor. Based on early clinical research, one treatment with IGV-001 has the potential to trigger a multi-pronged immune response, including a short-term innate immune response followed by longer-term powerful adaptive immune activity, that is selectively directed at the patients’ tumor cells.
IGV-001 has been granted orphan drug designation for the treatment of malignant glioma by the U.S. Food and Drug Administration and the European Medicines Agency.
About Imvax, Inc.
Imvax is a discovery and clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs. Imvax’s lead product candidate, IGV-001, is an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the patient’s immune system as a defense mechanism.
Imvax is based in Philadelphia, PA. For additional information, please visit www.Imvax.com.
+41 43 268 32 31